Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
about
Anti-angiogenesis and metastasis: a tumour and stromal cell allianceMouse models for studying angiogenesis and lymphangiogenesis in cancerThe role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitorsAn ex vivo model for anti-angiogenic drug testing on intact microvascular networksAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells.Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastasesNeoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Emerging roles of post-translational modifications in signal transduction and angiogenesisVasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?Contrasting effects of sunitinib within in vivo models of metastasis.Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic disseminationInhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic miceThe VEGF signaling pathway in cancer: the road ahead.Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Controlling escape from angiogenesis inhibitors.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancerInvestigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.Exploring the role of endothelium in the tumour response to anti-angiogenic therapy.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.Assessing metastasis risk after pre-operative anti-angiogenic therapy.Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers.Ten years of anti-vascular endothelial growth factor therapy.Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone.
P2860
Q26862741-AD804AF8-44B1-48CF-9696-DA7F35E03768Q27003898-F5CAEFDD-632E-440E-9347-AE2EA1E4C709Q28081504-741F28C3-774B-4AB1-8A96-42CE1CF2DE16Q28543862-C5F17B76-0B2C-4C69-9ED6-5F957FDF9C2AQ30399006-B70524AB-16F8-49C2-AA33-E90852A3ECDCQ33413742-0E90DE29-5239-4F0C-9AD4-89BF25F20B95Q33770680-B5E7526F-FE80-46C5-9D5A-9CEA65C15B1FQ34182311-0A85C363-0401-4350-8074-0C0DE327D119Q34561406-6F487000-2766-47CE-85B5-426A2BAE50C1Q34880943-F9CB65F4-BCB4-43AB-A07E-3B677396AE0CQ34978408-2797DBD3-87B1-465A-9D47-A4FD375B45E4Q35695381-A941DFD6-C27F-4310-9C8E-DC599E34AC6FQ35898650-6D027C00-C9F6-4A1A-B5F2-2ED222EDBD80Q36394262-88AB8915-CD5A-4BF4-A8B9-3C4010568EB4Q36468606-182AC185-6858-4DFF-B911-9E75793A3ADEQ36694132-5D3E5197-7A81-4AD0-8BBF-365A4EEA2EBFQ36941168-08AEFAA1-46B7-4C73-A8EA-55BC332759B4Q37354128-772D1E12-A401-4FBC-873F-1E6BBB111788Q37562355-40B524C7-DDFB-4C87-B5AC-3F60A2C3CDBBQ37672654-B9A6FFA5-27F9-4FBC-8C9C-AE64BFD88B8EQ38125964-70162CC8-FE21-44FC-97E9-B2D298F9A234Q38193533-D85C0AFE-7E51-4213-A48C-3DDAC32A2417Q38268445-ADB3C027-AA3D-42F6-A1FD-AD799DFA78D4Q38365290-98B82943-47F7-462E-8417-1279932E490AQ39146399-A9456567-79AF-44AF-A8CA-F80E49802735Q39165264-EE54BF2D-7466-418A-957E-364B10C66683Q41742917-48D81313-365E-42DF-BA9C-257C79CA7E4EQ41884180-440FF030-084E-435D-AD9C-9E3DE1AF76D4Q42067472-65FAD234-8DE3-448C-B18C-2B90F47140D6Q46407140-89B28EE7-289C-49CA-94E8-BC0852AA12D8Q47218543-595ADA53-483A-4AAE-993C-F6D2CB78E428Q51530606-0F7652B4-DD72-46AD-AF32-7F1A864CD34FQ53193292-D66443AD-D0CA-4453-97F0-A249C84AF9A8
P2860
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Differential drug class-specif ...... el of angiogenesis inhibitors.
@en
Differential drug class-specif ...... el of angiogenesis inhibitors.
@nl
type
label
Differential drug class-specif ...... el of angiogenesis inhibitors.
@en
Differential drug class-specif ...... el of angiogenesis inhibitors.
@nl
prefLabel
Differential drug class-specif ...... el of angiogenesis inhibitors.
@en
Differential drug class-specif ...... el of angiogenesis inhibitors.
@nl
P2093
P2860
P356
P1476
Differential drug class-specif ...... el of angiogenesis inhibitors.
@en
P2093
Alicia S Chung
David Finkle
Franklin Peale
Guanglei Zhuang
Laszlo Komuves
Marcin Kowanetz
Napoleone Ferrara
P2860
P304
P356
10.1002/PATH.4052
P577
2012-07-03T00:00:00Z